US Drug Recall Register

Is Pine recalled?

Yes — there is an active recall. 82 ongoing FDA recalls mention Pine (685 total). Check the affected lots below.

Recalls are matched by product description. A recall usually affects specific lots, not every package of Pine. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed.

Class II · Moderate risk Terminated

NIFEdipine ER

Reason Labeling: Label Mixup: NIFEdipine ER, Tablet, 60 mg may have potentially been mislabeled as the following drug: NICOTINE POLACRILEX, LOZENGE, 2 mg, NDC 00135051001, Pedigree: W003749, EXP: 6/26/2014.

Aidapak Services, LLC D-970-2014
Class II · Moderate risk Terminated

Loxapine

Reason Labeling: Label Mixup: LOXAPINE, Capsule, 5 mg may have potentially been mislabeled as the following drug: SERTRALINE HCL, Tablet, 50 mg, NDC 16714061204, Pedigree: AD46426_1, EXP: 5/15/2014.

Aidapak Services, LLC D-961-2014
Class II · Moderate risk Terminated

Atropine Sulfate/Diphenoxylate HCL

Reason Labeling: Label Mixup: ATROPINE SULFATE/DIPHENOXYLATE HCL, Tablet, 0.025 mg/2.5 mg may have potentially been mislabeled as the following drug: CYANOCOBALAMIN, Tablet, 1000 mcg, NDC 00536355601, Pedigree: AD65475_25, EXP: 5/28/2014. TRI-BUFFERED ASPIRIN, Tablet, 325 mg, NDC 00904201559, Pedigree: W003581, EXP: 6/24/2014.

Aidapak Services, LLC D-891-2014
Class II · Moderate risk Terminated

amLODIPine BESYLATE

Reason Labeling: Label Mixup: amLODIPine BESYLATE, Tablet, 5 mg may have potentially been mislabeled as the following drug: CYANOCOBALAMIN, Tablet, 1000 mcg, NDC 00904421713, Pedigree: W002839, EXP: 6/7/2014.

Aidapak Services, LLC D-843-2014
Class II · Moderate risk Terminated

carBAMazepine ER

Reason Labeling: Label Mixup: carBAMazepine ER, Tablet, 100 mg may have potentially been mislabeled as one of the following drugs: ISOSORBIDE DINITRATE ER, Tablet, 40 mg, NDC 57664060088, Pedigree: AD23082_4, EXP: 5/3/2014; SIROLIMUS, Tablet, 1 mg, NDC 00008104105, Pedigree: W003329, EXP: 6/18/2014.

Aidapak Services, LLC D-820-2014
Class II · Moderate risk Terminated

amLODIPine BESYLATE

Reason Labeling:Label Mixup; amLODIPine BESYLATE, Tablet, 10 mg may be potentially mislabeled as FINASTERIDE, Tablet, 5 mg, NDC 16714052201, Pedigree: AD62846_1, EXP: 2/28/2014.

Aidapak Services, LLC D-726-2014
Class II · Moderate risk Terminated

carBAMazepine ER

Reason Labeling:Label Mixup; carBAMazepine ER, Capsule, 200 mg may be potentially mislabeled as ACAMPROSATE CALCIUM DR, Tablet, 333 mg, NDC 00456333001, Pedigree: AD46333_1, EXP: 5/15/2014.

Aidapak Services, LLC D-719-2014
Class II · Moderate risk Terminated

PHENobarbital/ HYOSCYAMINE/ ATROPINE/ SCOPOLAMINE

Reason Labeling:Label Mixup; PHENobarbital/ HYOSCYAMINE/ ATROPINE/ SCOPOLAMINE, Tablet, 16.2 mg/0.1037 mg/0.0194 mg/0.0065 mg may be potentially mislabeled as VALSARTAN, Tablet, 160 mg, NDC 00078035934, Pedigree: W003639, EXP: 6/25/2014.

Aidapak Services, LLC D-718-2014
Class II · Moderate risk Terminated

QUEtiapine FUMARATE

Reason Labeling:Label Mixup; QUEtiapine FUMARATE, Tablet, 25 mg may be potentially mislabeled as chlordiazePOXIDE HCl, Capsule, 25 mg, NDC 00555015902, Pedigree: AD49426_1, EXP: 5/16/2014.

Aidapak Services, LLC D-716-2014
Class II · Moderate risk Terminated

OXcarbazepine Tablet

Reason Labeling:Label Mixup; OXcarbazepine Tablet, 600 mg may be potentially mislabeled as LACTASE ENZYME, Tablet, 3000 units, NDC 24385014976, Pedigree: AD30028_25, EXP: 5/7/2014.

Aidapak Services, LLC D-674-2014
Class II · Moderate risk Terminated

OXcarbazepine Tablet

Reason Labeling:Label Mixup; OXcarbazepine Tablet, 150 mg may be potentially mislabeled as traZODone HCl, Tablet, 50 mg, NDC 50111043301, Pedigree: AD54562_1, EXP: 5/20/2014.

Aidapak Services, LLC D-673-2014
Class II · Moderate risk Terminated

QUEtiapine FUMARATE Tablet

Reason Labeling:Label Mixup; QUEtiapine FUMARATE Tablet, 100 mg may be potentially mislabeled as DOCUSATE CALCIUM, Capsule, 240 mg, NDC 00536375501, Pedigree: W002776, EXP: 6/6/2014; NICOTINE POLACRILEX, Lozenge, 2 mg, NDC 37205098769, Pedigree: W003823, EXP: 6/27/2014; DOCUSATE SODIUM, Capsule, 250 mg, NDC 00536375710, Pedigree: AD60578_5, EXP: 5/29/2014.

Aidapak Services, LLC D-665-2014
Class II · Moderate risk Terminated

QUEtiapine FUMARATE

Reason Labeling:Label Mixup; QUEtiapine FUMARATE, Tablet, 25 mg may be potentially mislabeled as MULTIVITAMIN/MULTIMINERAL, Chew Tablet, NDC 58914001460, Pedigree: AD32325_1, EXP: 5/9/2014; ASPIRIN DR EC, Tablet, 81 mg, NDC 00182106105, Pedigree: W003094, EXP: 6/13/2014.

Aidapak Services, LLC D-664-2014
Class II · Moderate risk Terminated

Olanzapine

Reason Labeling:Label Mixup; OLANZAPINE, Tablet 7.5 mg may be potentially mislabeled as NORTRIPTYLINE HCL, Capsule, 75 mg, NDC 00093081301, Pedigree: AD21790_73, EXP: 5/1/2014.

Aidapak Services, LLC D-663-2014
Class II · Moderate risk Terminated

MIRTAZAPINE Tablet

Reason Labeling:Label Mixup; MIRTAZAPINE Tablet, 7.5 mg may be potentially mislabeled as ISONIAZID, Tablet, 300 mg, NDC 00555007102, Pedigree: W003691, EXP: 6/26/2014.

Aidapak Services, LLC D-646-2014
Class II · Moderate risk Terminated

MIRTAZAPINE Tablet

Reason Labeling:Label Mixup; MIRTAZAPINE Tablet, 7.5 mg may be potentially mislabeled as BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg, NDC 00574010603, Pedigree: AD73525_40, EXP: 5/30/2014; DULoxetine HCl DR, Capsule, 20 mg, NDC 00002323560, Pedigree: W003005, EXP: 6/11/2014; carBAMazepine ER, Tablet, 100 mg, NDC 00078051005, Pedigree: W003330, EXP: 6/18/2014.

Aidapak Services, LLC D-645-2014
Class II · Moderate risk Terminated

NIFEdipine Capsule

Reason Labeling:Label Mixup; NIFEdipine, Capsule, 10 mg may be potentially mislabeled as NITROFURANTOIN MONOHYDRATE/ MACROCRYSTALS, Capsule, 100 mg, NDC 47781030301, Pedigree: AD52778_58, EXP: 5/20/2014.

Aidapak Services, LLC D-644-2014
Class II · Moderate risk Terminated

OLANZapine Tablet

Reason Labeling:Label Mixup; OLANZapine, Tablet, 7.5 mg may be potentially mislabeled as LEVOTHYROXINE SODIUM, Tablet, 175 mcg, NDC 00527135001, Pedigree: AD46265_37, EXP: 5/15/2014; LEVOTHYROXINE SODIUM, Tablet, 88 mcg, NDC 00781518392, Pedigree: AD60272_73, EXP: 5/22/2014; MIRTAZAPINE, Tablet, 7.5 mg, NDC 59762141503, Pedigree: AD73525_55, EXP: 5/30/2014.

Aidapak Services, LLC D-619-2014
Class II · Moderate risk Terminated

carBAMazepine ER Tablet

Reason Labeling: Label Mixup; carBAMazepine ER Tablet, 200 mg may be potentially mislabeled as ACARBOSE, Tablet, 25 mg, NDC 00054014025, Pedigree: AD60272_1, EXP: 5/22/2014.

Aidapak Services, LLC D-604-2014
Class II · Moderate risk Terminated

QUETIAPINE FUMARATE Tablet

Reason Labeling: Label Mixup; QUETIAPINE FUMARATE Tablet, 12.5 mg (1/2 of 25 mg) may be potentially mislabeled as SIMVASTATIN, Tablet, 40 mg, NDC 00093715598, Pedigree: AD22845_4, EXP: 5/2/2014.

Aidapak Services, LLC D-575-2014
Class II · Moderate risk Terminated

NIFEDIPINE Capsule

Reason Labeling: Label Mixup; NIFEDIPINE Capsule, 10 mg may be potentially mislabeled as MULTIVITAMIN/MULTIMINERAL W/FLUORIDE, Chew Tablet, 1 mg (F), NDC 64376081501, Pedigree: AD22609_7, EXP: 5/2/2014; NIFEDIPINE, Capsule, 10 mg, NDC 43386044024, Pedigree: AD23082_7, EXP: 9/23/2013.

Aidapak Services, LLC D-565-2014
Class II · Moderate risk Terminated

Benztropine Mesylate Injection

Reason Presence of particulate matter: characterized as thin colorless flakes that are visually and chemically consistent with glass delamination observed in reserve sample vials

Fresenius Kabi USA, LLC NDC 63323-970-02 D-685-2013
Class II · Moderate risk Terminated

Belladonna Alkaloids/PB

Reason Presence of Foriegn Substance:The manufacturer, West-ward Pharmaceutical, recalled product because of the presence of black spots on tablets. In response, the repackager initiated its own recall.

Physicians Total Care, Inc. NDC 54868-0031-04 D-826-2013
Class II · Moderate risk Ongoing

Atropine Sulfate 50 mg/ml Injection

Reason Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-702-2013
Class II · Moderate risk Terminated

INK-EEZE Tattoo Black Label Numbing Spray

Reason Marketed without an approved NDA/ANDA: INK-EEZE Tattoo Numbing Spray contains 5% Lidocaine and is being marketed without an approved NDA/ANDA. Lidocaine 5% is an ingredient in many FDA approved products, making Ink-Eeze an unapproved new drug.

Indelicare LLC D-622-2013